Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression
Value in Health Regional Issues March 1, 2026 Yosr Ziadi, Taehwan Park 1 citation
Psilocybin-assisted therapy (PAT) for treatment-resistant depression (TRD) may be cost-effective compared with standard care. A modeling analysis from a US healthcare perspective found PAT to be more effective and less costly, saving about $7,000 and gaining 0.10 quality-adjusted life-years per patient over the short term. Over a 30-year horizon, savings increased to $215,900 with gains of 9.87 QALYs. These economic advantages persisted across variations in dosing, retreatment strategies, and psilocybin prices. The analysis suggests that early clinical benefits from PAT offset downstream chronic care costs, but longitudinal real-world evidence is needed to confirm these findings.